US Patent 4,626,531 (Labor/Abortion Prostaglandin + Antigestagen): Claim Scope and Patent Landscape
What does US 4,626,531 claim at the core?
US 4,626,531 claims pharmaceutical compositions and methods that combine (i) a labor- or abortion-inducing prostaglandin and (ii) a labor- or abortion-inducing antigestagen, where the combined total amount is effective to induce either labor or abortion. The claims then narrow by dose fractionation (lower-than-monotherapy amounts), fixed prostaglandin:antigestagen weight ratios, and specific chemical exemplars for both drug classes. [1]
Core claim architecture (independent claims and their dependency pattern)
- Composition (claim 1): any prostaglandin (class-labeled as labor/abortion inducing) + any antigestagen (class-labeled as labor/abortion inducing) in an effective total amount.
- Lower-than-monotherapy formulation (claims 2-3): at least one or both components are dosed below their standalone induction-effective amounts, while the combination still induces labor/abortion.
- Fixed weight ratio (claim 4): prostaglandin:antigestagen 1:20 to 1:6000.
- Dosage-unit packaging options (claims 5-6): separate dosage units or same dosage unit.
- Chemical specificity (claims 7-10, 11-13): specific prostaglandin and antigestagen molecules plus dose ranges and administration adaptation.
- Methods (claims 14-15; 22-31): induce abortion or induce labor via administering compositions of earlier claims; includes simultaneous vs sequential administration and whether in separate dosage units.
This is a classic “combination plus reduced-dose synergy” structure: broad enough to cover many prostaglandin/antigestagen pairings, but anchored with concrete ratio and dose specifications and with exemplar molecules.
What is the exact claim scope of the composition?
Claim 1 (composition baseline)
“A pharmaceutical composition comprising a labor or abortion inducing prostaglandin and a labor or abortion inducing antigestagen, the total amount of the combination … being effective to induce labor or an abortion.” [1]
Scope implications
- The claim is not limited to any single prostaglandin or antigestagen structure in claim 1 itself.
- It is limited by functional labeling: each component must be a “labor or abortion inducing” prostaglandin/antigestagen.
- It is limited by outcome: the combined total amount must be effective to induce labor or abortion.
Claim 2 and claim 3 (reduced individual component dosing)
- Claim 2: both the prostaglandin and the antigestagen amounts are lower than the amounts each is effective to induce labor/abortion when used alone. [1]
- Claim 3: at least one component is below its standalone effective amount. [1]
Practical legal reading
- Claim 2 is the tighter “both reduced” subset.
- Claim 3 is the broader “one reduced” subset.
- Both claims effectively require a combination effect that restores efficacy despite reduced individual dosing.
Claim 4 (weight ratio gate)
- Prostaglandin:antigestagen weight ratio 1:20 to 1:6000. [1]
Scope implications
- This ratio is a hard numeric limitation for claim 4 and any dependent method/composition claim referencing claim 4.
- Claim 1 by itself does not include a ratio restriction; it is only introduced in claim 4.
Claims 5-6 (dose unit arrangement)
- Separate dosage units (claim 5): prostaglandin and antigestagen are contained in separate dosage units. [1]
- Same dosage unit (claim 6): prostaglandin and antigestagen are contained in the same dosage unit. [1]
Scope implications
- The claims cover both co-packaged and fractionated administration formats.
- The same substantive chemical ratio and dosing logic can apply to either packaging model depending on which dependent claim is asserted.
How narrow are the composition claims when specific molecules are used?
Claim 7 (prostaglandin exemplar + dose range)
- Prostaglandin: 0.03–0.5 mg of 16-phenoxy-ω-17,18,19,20-tetranor-PGE2-methylsulfonylamide (or biologically equivalent prostaglandin). [1]
Claim 8 (antigestagen exemplar + dose range)
- Antigestagen: 10–200 mg of 11β-[(4-N,N-dimethylaminophenyl]-17β-hydroxy-17α-propinyl-4,9(10)-estradien-3-one (or biologically equivalent antigestagen). [1]
Together, claims 7 and 8 lock the combination to specific “representative” molecules and numeric dosing windows. They also retain the “biologically equivalent” language that can extend coverage to close analogs.
Claim 9 (expanded prostaglandin list)
Claim 9 enumerates multiple prostaglandin/prostaglandin-F/prodrug-like or structurally related candidates, including:
- PGE2
- several tetranor-PGE2 related methylsulfonylamide references
- PGF2α derivatives
- chlorinated/brominated/fluorinated variants and related “DE-OS 31 26 924” cited analogs
All as “biologically equivalent amount” and framed as satisfying the labor/abortion inducing prostaglandin requirement via the earlier functional language. [1]
Claim 10 (expanded antigestagen list)
Claim 10 enumerates multiple antigestagen structures, including variants of the 11β-(dimethylaminophenyl) estradienone scaffold and related substitutions (e.g., N,N-dimethylamino variants, methoxyphenyl, and other propinyl/hydroxyl and ring-modified analogs). [1]
Claims 11-13 (administration adaptation + more specific prostaglandin dosing)
- Claim 11: prostate dose 0.1–0.3 mg of 16-phenoxy-ω-tetranor-PGE2-methylsulfonylamide (or equivalent) and “adapted for i.m. or i.v. administration.” [1]
- Claim 12: prostaglandin dose 0.03–0.5 mg and “adapted for local administration.” [1]
- Claim 13: antigestagen 10–200 mg per dosage unit of the specified 11β-dimethylaminophenyl propinyl estradien-3-one scaffold (or equivalent). [1]
Scope implications
- These dependent claims add constraints on route/adaptation and narrower prostaglandin dose banding.
- The molecule lists in claims 9 and 10 support infringement coverage even if a competitor avoids the exact claim 7/8 scaffold, as long as the candidate matches one of the enumerated prostaglandins/antigestagens or is argued as a “biologically equivalent amount.”
What is the exact method claim scope?
Baseline method claims
- Claim 14: method of inducing abortion by administering an effective amount of a composition of claim 1. [1]
- Claim 15: method of inducing labor by administering an effective amount of a composition of claim 1. [1]
Administration timing and packaging (simultaneous vs sequential)
For abortion (claim 16 dependent on claim 14):
- prostaglandin and antigestagen administered simultaneously. [1]
For labor (claim 20 dependent on claim 15):
- prostaglandin and antigestagen administered simultaneously. [1]
For both abortion and labor, the patent also covers sequential administration and separate dosage units:
- Claim 17: sequential (depends on claim 14). [1]
- Claim 18: separate dosage units (depends on claim 14). [1]
- Claim 19: simultaneous (depends on claim 15) (note: your claim list includes both claim 19 and claim 20; the substantive idea is simultaneous as a dependent limitation). [1]
- Claim 21: separate dosage units (depends on claim 15). [1]
Method claims tied to narrower composition limitations
The patent then adds method coverage that is explicitly constrained to the reduced-dose and molecule-specific composition claims:
- Claims 22-23: abortion/labor using compositions of claim 3 (reduced dosing where at least one component is below monotherapy effective amount). [1]
- Claims 24-25: abortion/labor using compositions of claim 7 (specific prostaglandin and dose range). [1]
- Claims 26-27: abortion/labor using compositions of claim 8 (specific antigestagen and dose range). [1]
- Claims 28-29: abortion/labor using compositions of claim 9 (prostaglandin list). [1]
- Claims 30-31: abortion/labor using compositions of claim 10 (antigestagen list). [1]
What are the main infringement “gates” a designer must clear?
Gate set derived directly from claim limitations
A product must satisfy the earlier composition claim dependencies. In practice, the tightest gates are usually:
- Outcome: labor or abortion induced by effective total amount. [1]
- Component identity class: prostaglandin and antigestagen each must be “labor/abortion inducing” (broad functional hook in claim 1). [1]
- Reduced monotherapy dosing: claim 2 or claim 3 requires one or both components to be below their standalone effective doses. [1]
- Ratio: claim 4 requires prostaglandin:antigestagen weight ratio between 1:20 and 1:6000. [1]
- Dose unit arrangement: claims 5-6 and 18/21 and related method dependents. [1]
- Specific scaffold and numeric dose: claims 7-8, and the molecule lists in claims 9-10, plus administration adaptations in claims 11-12 and the antigestagen-per-dosage-unit framing in claim 13. [1]
“Easy-to-hit” claim sets for enforcement
- General combination enforcement: claim 14/15 (claim 1 composition). [1]
- Synergy/reduced dosing enforcement: claim 22/23 via claim 3, and claim 2 (if asserted). [1]
- Formulation rationing enforcement: claim 4 via any claim set that references claim 4 (your provided claim list includes claim 4 but does not show further dependents that explicitly hinge on it beyond claim 4 itself). [1]
- Route-and-dose enforcement: claims 11 and 12 for i.m./i.v. vs local administration. [1]
- Scaffold-specific enforcement: claims 24-31 anchor to prostaglandin or antigestagen exemplars and lists. [1]
How broad is US 4,626,531 relative to the typical mifepristone-misoprostol landscape?
US 4,626,531’s claim language is structured to cover any prostaglandin labor/abortion inducing agent plus any antigestagen labor/abortion inducing agent, subject to dose/range and ratio limitations in dependent claims. [1]
Even without mapping each specific enumerated molecule to a known market drug, the claim set is framed around:
- antigestagen steroids with propinyl substitutions and estradienone-type scaffolds (claims 8-10) [1]
- prostaglandin analogs that include PGE2/PGF2α derivatives and tetranor-PGE2 methylsulfonylamide scaffolds (claims 7-9) [1]
- numeric dose windows (prostaglandin 0.03–0.5 mg; antigestagen 10–200 mg) [1]
- combination dosing that permits reduced monotherapy amounts (claims 2-3) [1]
This creates a landscape posture where the patent can reach beyond a single fixed “pair” if the competitor uses a functionally equivalent prostaglandin and antigestagen meeting the claim constraints.
What does the patent landscape look like around this patent?
Landscape by claim “families” (what other assets typically exist)
The landscape around this kind of combination usually clusters into:
- antigestagen monotherapy patents (e.g., steroidal progesterone receptor antagonists with various dosing regimens)
- prostaglandin analog patents (methods/formulations for inducing labor or abortion)
- combination and timing regimen patents (including simultaneous vs sequential dosing)
- reduced-dose/synergy patents (attempts to lower dose per component)
- route-specific formulation patents (local vs systemic administration)
US 4,626,531 is positioned most strongly in the combination and reduced-dose cluster, with scaffold-specific coverage that can overlap with monotherapy patent estates and with later combination regimens. [1]
Citation signals inside the patent
Within the claim set, the patent references specific European-style prior art disclosures in the prostaglandin list: “(DE-OS 31 26 924)” appears embedded in claim 9’s prostaglandin enumerations. [1]
That indicates the asset was drafted with an awareness of already-disclosed prostaglandin structures, but it still claims the combination and dose/ratio framework around them.
Competitive freedom-to-operate (FTO) implications from claim scope
Where competitors have the hardest time designing around
A competitor trying to avoid infringement would need to manage at least one of these dimensions:
- avoid the same combination (both a prostaglandin and an antigestagen of the claimed class) while still achieving the same clinical outcome
- avoid the reduced dosing premise in claims 2-3 if asserting those dependents
- avoid the specific ratio window in claim 4 (if that dependent is asserted)
- avoid the enumerated prostaglandin or antigestagen scaffolds or the “biologically equivalent” hook (claims 7-10)
- avoid the claimed dose ranges (0.03–0.5 mg prostaglandin; 10–200 mg antigestagen) if dependents 7-8, 11-13 are asserted
- avoid claimed administration adaptations (i.m./i.v. vs local) in claims 11-12 if those dependents are asserted [1]
Where competitors may have more design room
- If a competitor uses a different class of abortion/labor inducer that is not a prostaglandin or not an antigestagen as framed by the patent, claim 1 scope may not be met.
- If the competitor uses different dosing logic such that neither component is below its monotherapy effective amount, claims 2-3 may not be met, though claims 14-15 could still be asserted under claim 1. [1]
Claim-to-portfolio mapping: what to monitor in follow-on filings
When scanning continuation, improvement, or licensing patterns, focus on:
- dose optimization arguments that explicitly target the below-monotherapy effective amount language (claims 2-3) [1]
- explicit ratio selection that falls outside 1:20 to 1:6000 (claim 4) [1]
- route claims matching or diverging from i.m./i.v. vs local (claims 11-12) [1]
- product packaging: separate vs same dosage unit (claims 5-6 and method dependents 18/21) [1]
- scaffold substitution strategies: whether analogs are argued to be “biologically equivalent” (claims 7-10) [1]
Key Takeaways
- US 4,626,531 claims labor/abortion-inducing prostaglandin + labor/abortion-inducing antigestagen combinations where the combined total is effective. [1]
- Dependent claims harden scope using: reduced-dose vs monotherapy (claims 2-3), a numeric weight ratio 1:20 to 1:6000 (claim 4), and dosage unit arrangement (claims 5-6). [1]
- The strongest enforcement vectors are the reduced-dose dependents and the scaffold-specific dependents with numeric dosing windows: prostaglandin 0.03–0.5 mg and antigestagen 10–200 mg, plus administration adaptation (claims 7-13). [1]
- Method coverage spans abortion and labor, with simultaneous vs sequential and separate dosage units limitations (claims 14-21), and then narrows to the reduced-dose and specific scaffold composition claims (claims 22-31). [1]
FAQs
1) Does US 4,626,531 require both components to be dosed below monotherapy levels?
No. Claim 3 requires at least one component to be below its monotherapy effective amount; claim 2 requires both. Claim 1 does not require reduced dosing. [1]
2) Is the prostaglandin:antigestagen ratio mandatory for every claim?
No. The ratio limitation is in claim 4 (1:20 to 1:6000). Claim 1 is not ratio-limited unless a dependent claim incorporating claim 4 is asserted. [1]
3) Can the prostaglandin and antigestagen be in the same pill?
Yes. Claim 6 covers both in the same dosage unit, while claim 5 covers separate dosage units. [1]
4) Does the patent cover both abortion and labor methods?
Yes. Claims 14-15 cover the general method for abortion and labor using claim 1 compositions; claims 22-31 cover additional narrower composition-based method variants. [1]
5) Are administration route and timing part of the protected scope?
Yes. The method claims include simultaneous vs sequential administration, separate dosage units, and composition dependents specify i.m./i.v. vs local adaptation. [1]
References
[1] United States Patent US4626531. “Pharmaceutical compositions and methods for inducing labor or abortion using a prostaglandin and an antigestagen.” (Claims 1-31 as provided in the request).
